Rozerem for sleep side effects, 8 mg by Ray Sahelian, M.D.
March 1 2016

Rozerem is a medication approved for insomnia treatment. Rozerem (known generically as ramelteon), acts in the same way as melatonin, the natural hormone that has been linked to healthy sleep in numerous studies. In one study, For more information on natural insomnia cures.

Res Rep Urol. 2013. Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients with insomnia associated with lower urinary tract symptoms. This study was conducted to examine the therapeutic efficacy and anti-inflammatory effect of ramelteon in elderly patients with insomnia associated with lower urinary tract symptoms (LUTS), who visited our urology department. The study included 115 patients (102 men, 13 women) who scored ≥4 on the Athens Insomnia Scale and who wished to receive treatment. The assessment scales for therapeutic efficacy included the International Prostate Symptom Score (IPSS) for LUTS and the Insomnia Severity Index (ISI) for sleep disorders. The high-sensitivity C-reactive protein (hs-CRP) test was used to an objective assessment. The patients were treated with ramelteon (8 mg/day) for an average of 10 weeks and were then reexamined using the questionnaires and hs-CRP test to evaluate therapeutic efficacy IPSS total scores declined significantly. ISI total scores improved significantly. The levels of hs-CRP decreased significantly. The ISI scores ≥ 10 (n = 51) showed a weak correlation with the hs-CRP levels. Rozerem had a systemic anti-inflammatory effect and improved sleep disorders and LUTS, suggesting that it may be a useful treatment for patients with LUTS-associated insomnia.

Rozerem side effects
Rozerem had no significant effects on cognition or movement control and no apparent potential for abuse according Archives of General Psychiatry, October 2006. But others report rozerem side effects to include impairment of thinking, drowsiness, and sleepiness the morning after use. Do not drink alcohol while you are taking ramelteon.

Psychopharmacology (Berl). 2015. The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers. :Hypnotics are widely used to treat insomnia but adverse effects of different hypnotics, especially benzodiazepine receptor agonists, are getting more attention lately. The effects of novel hypnotics have not been fully examined. Rozerem may affect road-tracking performance, visual attention and/or psychomotor speed measured by Trail-Making Test part A, and body balance in acute dosing. Lower dose of triazolam also impaired performance worse than Rozerem. Physicians should consider risks and benefits when prescribing both drugs, especially in the initial period of administration.

Rozerem for women after menopause
Rozerem Ramelteon for the treatment of insomnia in menopausal women.
Menopause Int. 2009; Dobkin RD, Menza M, Bienfait KL, Allen LA, Marin H, Gara MA. Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ, USA.
The goal of this study was to evaluate the effect of Rozerem, a selective melatonin receptor agonist, for the treatment of menopausal insomnia. STUDY DESIGN: A total of 20 healthy peri- and postmenopausal women with insomnia participated in this six-week, prospective, open-label trial of Rozerem (8 mg) at an academic medical centre. Participants completed sleep-wake diaries on a daily basis for six weeks. Self-report measures of sleep impairment, daytime functioning, quality of life and mood were also completed on a bi-weekly basis. Significant improvements in latency to sleep onset, total sleep time and sleep efficiency were observed in diary data while gains in sleep quality, sleep impairment, daytime functioning, quality of life and mood were found in self-report measures. There was no evidence of tolerance or rebound over the course of the trial. Overall, results suggest that Rozerem is an effective non-hormonal approach for the treatment of insomnia in menopause. Randomized-controlled trials are needed to further evaluate the efficacy of this intervention.